VEGF signaling through its tyrosine kinase receptor, VEGFR2 (FLK1), is critical for tumor angiogenesis. Previous studies have identified a critical gene dosage effect of VegfA in embryonic development and vessel homeostasis, neovascularization, and tumor growth, and potent inhibitors of VEGFR2 have been used to treat a variety of cancers. Inhibition of FGFR signaling has also been considered as an antiangiogenic approach to treat a variety of cancers. Inhibition of VEGFR2 with neutralizing antibodies or with pharmacological inhibitors of the VEGFR tyrosine kinase domain has at least short-term efficacy with some cancers; however, also affects vessel homeostasis, leading to adverse complications. We investigate gene dosage effects of Vegfr2, Fgfr1, and Fgfr2 in three independent mouse models of tumorigenesis: two-stage skin chemical carcinogenesis, and sub-cutaneous transplantation of B16F0 melanoma and Lewis Lung Carcinoma (LLC). Mice heterozygous for Vegfr2 display profound defects in supporting tumor growth and angiogenesis. Unexpectedly, additional deletion of endothelial Fgfr1 and Fgfr2 in Vegfr2 heterozygous mice shows similar tumor growth and angiogenesis as the Vegfr2 heterozygous mice. Notably, hematopoietic deletion of two alleles of Vegfr2 had minimal impact on tumor growth, with little effect on angiogenesis, reinforcing the importance of endothelial Vegfr2 heterozygosity. These studies reveal previously unrecognized Vegfr2 gene dosage effects in tumor angiogenesis and a lack of synergy between VEGFR2 and endothelial FGFR1/2 signaling during tumor growth.
Results
Vegfr2 heterozygosity markedly inhibits chemically-induced skin carcinogenesis and angiogenesis. To better understand the VEGF signaling requirements in tumor angiogenesis, we assessed whether Vegfr2, similar to VegfA, exerts gene dosage effect in tumor angiogenesis. To this end, we took advantage of Vegfr2 Cre/+ or Vegfr2 LacZ/+ knock-in mice that are heterozygous for the Vegfr2 gene. We also included Fgfr1 f/f ; Fgfr2 f/f (double floxed, DFF, used as control) and Vegfr2 +/+ ; Fgfr1 f/f ; Fgfr2 f/f (double conditional knockout, DCKO) mice in the study, to determine the extent of crosstalk between VEGF and FGF signaling in tumor angiogenesis. Specifically, Vegfr2 Cre/+ ; Fgfr1 f/f ; Fgfr2 f/f (DFF control), and Vegfr2 Cre/+ ; Fgfr1 f/f ; Fgfr2 f/f (DCKO) mice were subjected to two-stage skin carcinogenesis 15 . Surprisingly, Vegfr2 Cre/+ mice displayed a striking resistance to papilloma development compared to control DFF mice throughout the 25 weeks of the study as shown by a significant (p < 0.001) decrease in average number and size of papillomas per mouse (Fig. 1a,b) . Interestingly, the DCKO mouse phenotype was very similar to that of Vegfr2 Cre/+ mice, suggesting lack of synergy between VEGFR2 and endothelial FGFR1/2 signaling in this model. To gain insight into the possible mechanisms underlying this phenotype, we determined whether there was any alteration in angiogenesis in the papilloma and adjacent skin. Immunohistological examination showed a similar reduction in vascular density in the papilloma and adjacent papilloma bearing skin in both Vegfr2 Cre/+ and DCKO mice compared to DFF mice ( Fig. 1c-f ). Taken together, these data suggest a potent gene dose effect of Vegfr2 (but not Fgfr1/2) on pathologic angiogenesis and tumorigenesis.
Vegfr2 heterozygosity impairs melanoma tumor growth and angiogenesis. To further study the effect of Vegfr2 heterozygosity, alone or in combination with endothelial Fgfr1/2 inactivation in an independent tumorigenesis model, we tested B16 melanoma cell growth when transplanted into mice. DFF, Vegfr2 Cre/+ , Vegfr2 lacZ/+ and DCKO mice received a single subcutaneous injection of B16F0 melanoma cells in their flanks. Consistent with the results from the two-stage chemical carcinogenesis model, Vegfr2 Cre/+ , Vegfr2 lacZ/+ as well as DCKO mice displayed a significant (p < 0.001) impairment in tumor growth compared to DFF littermate Results are mean ± SEM. Mann-Whitney U test was used to analyze significance (*p < 0.05; **p < 0.01; ***p < 0.001) compared to control. Where mouse number is unstated, each symbol represents one mouse. Ear skin sections with or without papillomas were imaged with a 10X objective.
SCIentIfIC REPORTS | (2018) 8:14724 | DOI:10.1038/s41598-018-33037-2 controls ( Fig. 2a,b ). Immunostaining and quantitation of histological sections for vascular and pericyte markers, MECA-32 and Desmin, showed a decrease in tumor angiogenesis in Vegfr2 Cre/+ and DCKO compared to DFF control mice ( Fig. 2c,d) . Although, mice with floxed alleles of Fgfrs do not have any identified phenotypes, we nevertheless compared tumor formation in wild type (WT) mice to Vegfr2 +/+ ; Fgfr1 f/f ; Fgfr2 f/f (DFF) control mice. As anticipated, these control genotypes were indistinguishable ( Supplementary Fig. S1 ).
Analysis of VEGFR1, VEGFR2, FGFR1, FGFR3 and VE-Cadherin expression levels in B16F0 melanoma cells, and tumors isolated from control and DCKO mice showed ~30% reduced levels of VEGFR2 (but not VEGFR1) in DCKO mice compared to DFF control littermates, consistent with Vegfr2 haploinsufficiency ( Supplementary  Fig. S2A,B ). Additionally, VE-Cadherin and FGFR1 levels were reduced in DCKO tumors compared to control tumors, reflective of reduced tumor angiogenesis and tumor endothelial Fgfr1 deletion ( Supplementary Fig. S2A ). Taken together, the B16F0 melanoma transplantation model confirmed a role for Vegfr2 gene dosage in regulating the sensitivity to transplanted melanoma tumor growth and tumor associated neovascularization and suggests that loss of endothelial FGFR1/2 signaling does not further enhance the effect of reduced VEGFR2 expression.
Vegfr2 heterozygosity markedly impairs Lewis lung carcinoma (LLC) tumor growth, angiogenesis, and VEGFR2 phosphorylation. We further tested the effects of Vegfr2 heterozygosity using a third independent tumor model: subcutaneous transplantation of the Lewis Lung Carcinoma (LLC) tumor cells. As we did not observe any phenotypic difference either between Vegfr2 Cre/+ and DCKO or DFF and wild-type (WT) in the previous two tumor models, we focused on comparing Vegfr2 Cre/+ with littermate WT controls. Similar to our observations with the previous two models, tumor growth was markedly impaired following tumor cell injection in Vegfr2 Cre/+ mice compared to wild type control littermates (designated Ctl) ( Fig. 3a) . Histological analysis revealed a significant (p < 0.001) reduction in angiogenesis similar to previous observations in the two tumor models described above (Fig. 3b,c ). Furthermore, immunostaining and quantitation of histological sections for perivascular markers, Desmin and αSMA, showed a decrease in tumor perivascular coverage in Vegfr2 Cre/+ compared to DFF control mice consistent with our observations in melanoma tumors ( Supplementary  Fig. S3A-D) . Immunostaining, to determine whether tumor inhibition could be explained by disrupted VEGFR2 phosphorylation in LLC tumor endothelium, showed reduced VEGFR2 tyrosine phosphorylation in tumors from Vegfr2 Cre/+ mice (Fig. 3b,c) . Taken together, these data further demonstrate the dose dependency of Vegfr2 for tumor endothelial activation, angiogenesis, and overall tumor growth. Hematopoietic cell Vegfr2 deletion minimally impacts tumor growth. Defects in tumor angiogenesis in Vegfr2 Cre/+ mice suggested the requirement of endothelial Vegfr2 in tumor angiogenesis. Given that Vegfr2 Cre/+ targets also hematopoietic cells 16 , we aimed at ruling out a possible contribution of hematopoietic Vegfr2 in tumor angiogenesis by specifically inactivating Vegfr2 in hematopoietic cells. The, Vav-Cre allele, which preferentially targets hematopoietic cells 17 was used to delete Vegfr2. Mice with the genotype Vav-Cre; Vegfr2 f/f were subcutaneously transplanted with LLC tumor cells and monitored for tumor growth for 20 days. Compared to Vegfr2 Cre/+ mice, a minimal tumor growth inhibition was observed in Vav-Cre; Vegfr2 f/f mice (Fig. 4a ). Notably, Vav-Cre; Vegfr2 f/f mice did not show any impairment in tumor angiogenesis, suggesting that the small reduction in tumor growth is endothelial cell independent ( Fig. 4b ). We confirmed efficient deletion of Vegfr2 in whole blood or CD31 − CD45 + hematopoietic cells from the lung, but not in CD31 + CD45 − endothelial cells ( Supplementary Fig. S4 ). Taken together, these data suggest a minimal role for hematopoietic Vegfr2 during tumor growth.
Lymphocyte or macrophage infiltration into the skin in response to TPA was unaffected by the
Vegfr2 and endothelial Fgfr1/2 deficiency. Inflammatory cells are known to support tumor angiogenesis. To exclude a possible role for Vegfr2 heterozygosity in immune cell infiltration, we profiled the expression of key inflammatory markers in response to TPA challenge at the same concentration used to promote ) mouse skin was stained for CD45 and F4/80 to identify leucocytes and macrophages, respectively. In response to twice weekly TPA treatments, there was a 3-fold increase in the number of CD45 positive inflammatory cells in both control and DCKO skin ( Fig. 5a,b ). However, there was no difference in CD45 + hematopoietic cell infiltration between the two genotypes. Also, control and DCKO mice showed similar expression of F4/80 positive macrophages after three TPA treatments in a seven-day study (Fig. 5c,d ). Consistent with these data, expression levels of inflammatory chemokines such as Tnfa, Il6, and Ptgs2 (Cox2) were increased (6-15 fold) in response to TPA treatment, but showed no difference relative to genotype ( Fig. 5e-g) . It is thought that VEGFR1 provides a migratory signal to inflammatory cells. We therefore examined Vegfr1 and Vegfr2 mRNA levels in skin challenged with TPA for seven days. While, Vegfr1 RNA levels were increased by four-fold in response to TPA, there was no difference between control and DCKO mice ( Supplementary Fig. S5A ). TPA also induced an increase in Vegfr2 mRNA levels in both control and DCKO mice; however, the increase in Vegfr2 RNA levels in DCKO mice was less than that in control mice ( Supplementary  Fig. S5B ). Together, these data show that lymphocyte or macrophage infiltration into the skin in response to TPA was not affected by Vegfr2 and endothelial Fgfr1/2 deficiency.
Discussion
The VEGF signaling pathway is the primary angiogenic target and is successfully being used in the clinic for the treatment of various malignancies by blocking either the ligand, VEGFA, or the receptor, VEGFR2 [18] [19] [20] . However, while cancer patients clearly benefit from anti-VEGF therapies, it comes with the cost of vascular-related side effects and complications, including abnormal blood pressure and thrombosis 3 . Additionally, the benefit of anti-VEGF therapy is short-lived and tumors inevitably escape this treatment and continue to grow [21] [22] [23] . Of the known anti-VEGF mechanisms of evasion, induction of compensatory pathways including FGFR activation is well documented 23 .
In the current study, we found that VEGFR2 signaling in hematopoietic cells was not required for tumor angiogenesis, as Vegfr2 deletion in hematopoietic cells minimally affected tumor angiogenesis. Interestingly, a recent study reported that VEGFR2 was required in hematopoietic cells for glioma progression; however, tumor angiogenesis was not examined in this study 24 . Future studies of contribution of VEGF signaling in hematopoietic cells to tumor growth independent of angiogenesis are therefore warranted.
While tumor growth and tumor angiogenesis was strikingly impaired by Vegfr2 heterozygosity, simultaneous inactivation of endothelial Fgfr1/2 did not enhance the tumor inhibitory effects, despite studies showing additive efficacy using pharmacological small molecular inhibitors targeting multiple tyrosine kinases 5, 25 . However, since endothelial cells also express Fgfr3 (but not Fgfr4) 26 , and upregulate Fgfr3 expression in the absence of Fgfr1 27 , it is possible that Fgfr3 could compensate for the Fgfr1 and Fgfr2 deficiency in tumor endothelial cells. Potential contributions of FGFR3 should be further investigated. Alternatively, non-endothelial FGFR signaling may contribute to cancer growth and choosing drugs with moderate VEGFR2 and FGFR1/2 inhibitory properties still should be considered and may be more efficacious and less toxic than strongly inhibiting both pathways. The abundant expression of FGFR1 in melanoma tumor cells shown here ( Supplementary Fig. SA) supports a potential non-endothelial role for FGFR1 in the growth of this tumor. In addition, the context dependence of FGF signaling in different cell types in tumors may explain differences in study outcomes between this work and others 28 . Future studies will be required to test the ability of mice conditionally lacking FGFRs 1, 2, and 3 in endothelial cells to support tumor growth with and without a wild type Vegfr2 allele. Lastly, while tumor angiogenesis clearly plays a role in the tumor phenotypes described in our studies, potential contributions of angiogenesis independent mechanisms such as vascular co-option, a process involving crawling along existing host vasculature by cancer cells to gain access to blood supply 29 , cannot be ruled out, particularly regarding the consequence of endothelial FGFR1/2 deletion. Of note, findings in the current study showing a lack of synergy between VEGFR2 and FGFR1/2 signaling during tumor growth are distinct from our previous study where Vegfr2 heterozygosity showed no effect on injury response, while Fgfr1/2 inactivation in endothelial and hematopoietic cells was required for neoangiogenesis in response to injury 13 . Additionally, endothelial inactivation of Fgfr1/2 impaired the heart's response to ischemia-reperfusion injury 30 . The role of Vegfr2 haploinsufficiency was not investigated in this model. These differences between FGFR and VEGFR2 signaling requirements highlight speculated and increasingly appreciated differences between the angiogenic response and signaling requirements of different vascular beds in the context of injury response and cancer. Future studies testing the role of Vegfr2 heterozygosity in other non-cutaneous tumor models and exploring whether there is a different outcome using inducible systems to temporally inactivate one allele of Vegfr2 are warranted.
The data presented here suggests that while Vegfr2 heterozygosity strikingly leads to defects in tumor growth and tumor angiogenesis in all the three tumor models, additional loss of endothelial Fgfr1 and Fgfr2 displays no further effects on tumor growth and tumor angiogenesis. The gene dosage of Vegfr2, but not endothelial Fgfr1/2, in tumor growth and pathologic neovascularization (Fig. 6) suggests that for optimal anti-angiogenic response and to minimize toxicity to the normal vasculature, partial pharmacological blockade of VEGFR2 signaling may be more efficacious and with fewer side effects than complete inhibition of VEGFR2 in some tumor types. 
Methods
Mice. Vegfr2 Cre/+14 , Vegfr2 LacZ/+31 , Vegfr2 Cre/+ ; Fgfr1 f/f ; Fgfr2 f/f (DCKO mice) 13 , Vegfr2 f/f32 , and Vav-Cre 17 mice were previously described. DCKO mice were shown to have an 84% reduction in Fgfr1 and 87% reduction in Fgfr2 expression in sorted lung endothelial cells and were phenotypically normal as adults 13 . Vegfr2 LacZ/+ or Vegfr2 Cre/+ (Vegfr2 +/− ), Vegfr2 +/+ ; Fgfr1 f/f ; Fgfr2 f/f (double floxed, DFF, control, designated Ctl), and Vegfr2 Cre/+ ; Fgfr1 f/f ; Fgfr2 f/f (double conditional knockout, DCKO) mice were maintained on an inbred C57BL/6 genetic background following ten generations of backcrossing to wild type C57BL/6 J mice. Vav-Cre and Vegfr2 f/f mice were also maintained on a C57BL/6 genetic background.
Cell lines. B16 melanoma cells (provided by Kathy Weilbaecher, Washington University) and Lewis lung carcinoma (LLC) cells (obtained from Alexander Krupnick, Washington University) were maintained in High Glucose DMEM (ThermoFisher Inc.), supplemented with 10% (v/v) FBS, 100 unit/ml penicillin and 100 μg/ml streptomycin.
Cancer models. For two stage chemical carcinogenesis, the back skin of each age-matched mouse was treated once with DMBA and repetitively with TPA for 25 weeks as previously described 15, 33, 34 . Specifically, the back skin of each age-matched (8-10 weeks old) mouse was shaved under anesthesia two days before topical treatment with a single dose of DMBA (0.1 mg/ml in acetone [or 25 µg in 200 µl acetone], MilliporeSigma Inc.). Beginning one week later, mice were topically treated twice weekly with TPA (12.5 µg in 200 ml acetone per treatment; MilliporeSigma Inc.) and monitored for 25 weeks. Control mice (n = 4) of each genotype were treated with acetone only. Papillomas >1 mm in diameter were counted over the course of TPA challenge and at necropsy.
For the B16 melanoma cell model 35, 36 1 × 10 6 cells were injected subcutaneously in the hind limb flank under anesthesia. Tumor growth was monitored and recorded over the course of the study. Tumors were excised and tumor weight determined at necropsy on day 14.
For the LLC cell model, 1 ml of growth factor reduced Matrigel: Matrix protein HC (Cat: 354248; Corning) was mixed with 1 ml of tumor cell suspension (2 × 10 6 /ml in PBS); 100 µl of tumor cell-Matrigel mixture was injected subcutaneously to the back of mice. Tumor growth was monitored and tumor volume recorded using digital slide calipers (VWR International) every other day from day 6 to day 20 after tumor cell inoculation. Tumor volume was calculated by the equation, Volume = (largest diameter) × (smallest diameter) 2 × 0.5.
TPA-induced cutaneous inflammation.
The dorsal back (shaved under anesthesia) or external ear skin was challenged with TPA (12.5 µg in 200 µl Acetone) or vehicle (acetone) twice per week. Mice were sacrificed on day 7, skin tissues were collected and processed for immunostaining or gene expression analysis.
Tissue harvest, Immunostaining, and Microscopy. Tissues were isolated and immunostained as previously described 13, 37 . At necropsy, papilloma, or papilloma bearing skin, B16F0 melanoma tumors, or LLC carcinoma tumors were excised, fixed either in 10% (vol/vol) buffered formalin for frozen sectioning or 70% (vol/vol) cold ethanol for paraffin embedding. Tumors harvested in 10% buffered formalin were immersed in 30% (w/v) sucrose solution for 48 h to cryo-protect the tissue, frozen in NEG-50 frozen section medium (Cat: 6502, ThermoFisher scientific) using liquid nitrogen and 2-methylbutane, and sectioned (16 µm) using a Cryostat Cryocut Microtome (Leica, CM1850, Nussloch, Germany). Frozen sections were first blocked at room temperature using freshly made blocking buffer (3% essentially IgG free BSA (Cat: A9085, MilliporeSigma Inc.), 0.3% Triton X-100, and Fc blocker (Cat: 101301, Biolegend)) to prevent non-specific binding. Additionally, formalin fixed paraffinized tissue sections (5 µm) were deparaffinized, washed in PBS, underwent antigen retrieval using a pressure cooker and citrate buffer (pH6) and blocked with antibody diluent plus 10% goat serum for 30 min at room temperature. Immunostaining of both the frozen and paraffinized tissue sections was carried out using the following reagents. 
Vascular Density Quantification. Vascular density was assessed by counting the number of CD31-or
Meca32-positive vessels in three fields (10X objective) per section per mouse (n = 3-16 mice). Alternatively, at least three images from every section per mouse (n = 5 mice) were processed using ImageJ software (NIH) to quantify CD31 and pFLK1 positive areas.
Immunoblotting. Western blots were performed as previously described 37 . Briefly, tissues were lysed in RIPA buffer with freshly added protease and phosphatase inhibitors (P8340, P5726 AND P0044; MilliporeSigma Inc.). Equal amounts of protein lysates were separated on SDS 4-12% polyacrylamide Tris-glycine gradient Midi gels (WT4121BX10; Invitrogen) and transferred to PVDF membranes (iBlot Gel Transfer Stacks PVDF Regular, IB4010-01; Invitrogen). Immunobloting was performed as previously described 13 . Briefly, skin, papilloma and tumors were excised. Tissues were homogenized in RIPA buffer with freshly added protease and phosphate Inhibitor cocktail and centrifuged to obtain lysates. Protein quantification was performed on clarified tissue lysates and then subjected to SDS-PAGE. Membranes were probed with the following primary antibody at 4 °C overnight except as otherwise stated: rabbit monoclonal VEGFR1 (ab3215, Abcam), rabbit monoclonal VEGFR2 (2479, Cell Signaling), VE-Cadherin (sc-6458; Santa Cruz), rabbit polyclonal FGFR1 (sc-121; Santa Cruz, FGFR3 antibody (generated by David M. Ornitz laboratory at Washington University in St. Louis). After overnight incubation, membranes were washed 3x and incubated for 1 hour at room temperature in horseradish peroxidase-conjugated anti-rabbit (1:2000, sc-2301; Santa Cruz) or anti-goat IgG antibodies (sc-2304; Santa Cruz in TBST with 5% nonfat milk and developed in SuperSignal West Femto Maximum Sensitivity Substrate (34096; Thermo Scientific). Membranes were stripped in multiple washes of boiled 100 mM glycine and washed three times in TBST for 10 min each (per iBlot stripping protocol; Invitrogen) at room temperature. Stripped membranes were then reprobed for β-tubulin (1:50,000, ab6046; Abcam). Protein bands were imaged using a BioRad ChemiDoc MP Imager.
Gene Expression Analysis. Tissue samples were homogenized in 1 ml TRIzol (#15596-018; Invitrogen).
Total RNA was isolated according to manufacturer's instructions. Total RNA, following TRIzol extraction, was further purified using RNeasy kit (Cat: 74106; Qiagen) and DNAse-treated on a column with RNAse Free DNAse set (Cat: 79254; Qiagen). Total RNA was transcribed into cDNA as per manufacturer's protocol. Real-time RT-PCR analysis was performed using inventoried TaqMan ® gene expression primers and probes (Additional file 1: Table S1 ). Target cDNAs were normalized to Gapdh. Quantitative RT-PCR assays were run using a TaqMan ® Applied Fast Advanced Mastermix according to the manufacturer's protocols (Cat: 4444557; ThermoFisher).
Statistical Analysis. Data Study Approval. Mice were housed in a pathogen-free facility and handled in accordance with standard use protocols, animal welfare regulations, and the NIH Guide for the Care and Use of Laboratory Animals. All protocols were approved by the Washington University in St. Louis Animal Care Committee and Institutional Biosafety.
